EVERSANA®, a leading provider of commercialization services to the global life sciences industry, has officially announced the launch of EVERSANA AI Accelerator, which happens to be a dedicated center of excellence (COE) focused on changing the ballgame of life sciences commercialization through AI.
To understand the significance of such a development, we must take into account one report from McKinsey Global Institute (MGI), which projects generative AI to produce between $60 billion- $110 billion in annual value across the pharmaceutical value chain, with $18 billion to $30 billion in commercialization alone.
“Innovation isn’t new to EVERSANA. From our COMPLETE Commercialization model to the use of agentic KOL influencers, evolution is in our DNA. Today, we give that spirit of transformation a home in our global enterprise,” said Jim Lang, Chief Executive Officer of EVERSANA. “We invite our clients and partners to collaborate and build what’s next.”
Talk about how EVERSANA’s latest brainchild can help organizations tap into this staggering potential, we begin from the promise of dedicated AI and commercialization expertise. This translates to how EVERSANA AI Accelerator will employ AI innovators, who are currently working with life sciences leaders, to reimagine global drug pricing, promotion, access, reimbursement, adherence, and product delivery challenges.
Next up, we have important technology partnerships coming into play. Here, the development will make a point to foster collaborations with leading technology companies such as Amazon Web Services, Google, Salesforce, Veeva, and Modus Create.
Almost like an extension of it, EVERSANA new AI Accelerator also enjoys representation from pharmaceutical and medical device companies and start-ups deploying or piloting new AI platforms and toolsets.
Rounding up highlights would be the prospect of breakthrough technology deployments. These deployments include integrating proprietary and/or third-party technologies into the AI-activated EVERSANA ORCHESTRATE™ Operating System.
Among other things, it would be acknowledged that recent deployments from the EVERSANA AI Accelerator include EVERSANA ORCHESTRATE MLR, which happens to be an AI-powered Medical, Legal & Regulatory platform that was recently awarded an Emerald Pinnacle Technology Award.
As for the AI Accelerator’s R&D pipeline, it is currently beta-testing advancements in pharmaceutical marketing, patient hub services, and wider end-to-end commercialization operations.
Founded in 2018, EVERSANA’s rise up the ranks stems from a portfolio of solutions that, on their part, span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company’s excellence in what it does can also be understood once you consider it serves, at the moment, more than 650 organizations, ranging from innovative start-ups and established pharmaceutical companies.
“Faruk (EVERSANA’s Chief Innovation Officer) and team have created the space where AI innovation in our complex sector is born. Not only is it transforming every facet of our operation, but it is also creating a healthier world,” said Lang. “Frankly, patients have waited far too long to reap the benefits of what’s possible when pharma commercialization is propelled by AI.”
